NCT02432963 2026-01-28Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyCity of Hope Medical CenterPhase 1 Active not recruiting11 enrolled
NCT05983133 2026-01-22A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsSeagen Inc.Phase 1 Active not recruiting65 enrolled
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT04708470 2025-12-31A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersNational Institutes of Health Clinical Center (CC)Phase 1/2 Active not recruiting55 enrolled
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT04354246 2025-05-22COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompugen LtdPhase 1 Active not recruiting110 enrolled
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled
NCT05572684 2024-12-16A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid TumorsNextCure, Inc.Phase 1/2 Active not recruiting97 enrolled